0.039

48.69% +0.0128

After Hours: .039

Nls Pharmaceutics Ag (NLSPW)

Overview News Price History Discussions Forecast

Nls Pharmaceutics Ag stock is currently priced at $0.039, with a 24-hour trading volume of 500. It has seen a +48.69% increased in the last 24 hours and a +94.03% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.0262 pivot point. If it approaches the $0.0262 resistance level, significant changes may occur.

Previous Close:

$0.0262

Open:

$0.039

24h Volume:

500

Market Cap:

$N/A

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+49.43%

1M Performance:

+94.03%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1D Range:

$0.039

52W Range:

$0.0111

$0.1001

Nls Pharmaceutics Ag Stock (NLSPW) Company Profile

Name

Nls Pharmaceutics Ag

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

41 44 512 21 50

Address

The Circle 6, Zurich

Employee

Twitter

Next Earnings Date

Latest SEC Filings

NLSPW's Discussions on Twitter

Nls Pharmaceutics Ag Stock (NLSPW) Financials Data

There is no financial data for Nls Pharmaceutics Ag (NLSPW). Check out other stocks for more information.

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.